Campbell & CO Investment Adviser LLC Genmab A/S Transaction History

Campbell & CO Investment Adviser LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$27.94 - $35.44 $1.65 Million - $2.09 Million	59,003 New	59,003 $1.88 Million
Q2 2023 Aug 11, 2023	SELL	$37.4 - $42.94 $424,078 - $486,896	-11,339 Reduced 41.78%	15,804 $600,000
Q1 2023 May 11, 2023	SELL	$34.88 - $43.22 $547,895 - $678,899	-15,708 Reduced 36.66%	27,143 $1.02 Million
Q4 2022 Feb 14, 2023	BUY	$33.8 - $47.06 $1.06 Million - $1.47 Million	31,291 Added 270.68%	42,851 $1.82 Million
Q3 2022 Nov 14, 2022	SELL	$31.52 - $373.61 $139,192 - $1.65 Million	-4,416 Reduced 27.64%	11,560 $371,000
Q2 2022 Aug 09, 2022	SELL	$26.83 - $38.57 $241,362 - $346,975	-8,996 Reduced 36.02%	15,976 $519,000
Q1 2022 May 09, 2022	BUY	$30.95 - $39.68 $772,883 - $990,888	24,972 New	24,972 $903,000
Q4 2021 Feb 10, 2022	SELL	$35.87 - $47.12 $299,514 - $393,452	-8,350 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$41.55 - $48.72 $91,410 - $107,184	2,200 Added 35.77%	8,350 $365,000
Q2 2021 Aug 11, 2021	BUY	$32.88 - $44.57 $202,212 - $274,105	6,150 New	6,150 $251,000

234

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.8B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.